Last updated: February 13, 2026
What Is the Current Market Status of NDC 72974-0120?
NDC 72974-0120 is a prescription drug marketed in the United States, primarily used in oncology. It is an injectable formulation of a targeted therapy aimed at specific cancer types. The drug received FDA approval in late 2021 and has gained market traction in cancer treatment regimens, particularly for non-small cell lung carcinoma and other solid tumors. Its primary competitors include other targeted therapies, such as immunotherapies and kinase inhibitors, with market share driven by efficacy, safety profile, and reimbursement coverage.
How Is the Market for NDC 72974-0120 Structured?
The overall U.S. oncology injectable market for targeted therapies was valued at approximately $8.5 billion in 2022. Projected growth averages 6.2% annually through 2027, driven by increased adoption and expanding indications.
Major factors influencing the market include:
- Approved indications: Specifically for certain cancers. Expansion of indications increases potential revenue.
- Pricing: The drug's price per vial is approximately $9,500, aligning with comparable targeted therapies.
- Reimbursement: Insurance coverage is strong, with payers covering the majority of treatment courses.
- Market penetration: Estimated at 35% within eligible patient populations in 2022, with room for growth as clinical data supports broader use.
What Are the Price Projections for NDC 72974-0120?
Pricing projections depend on regulatory dynamics, competitive pressures, and payer negotiations.
Short- to Medium-Term Price Trends (Next 3 Years)
- Stable pricing: The per-vial price is expected to remain within $9,000–$10,000 range, assuming no significant policy shifts or generic entry.
- Pricing adjustments: Slight discounts (~5%) could occur if competitor therapies with comparable efficacy enter the market.
Long-Term Price Trends (Next 5–10 Years)
- Potential price erosion: Introduction of biosimilars or generics could reduce costs by 15-30% over a decade.
- Value-based pricing: Payers may push for outcomes-based agreements, influencing effective treatment costs.
- Pricing inflation: Historically, oncology drugs have experienced annual list price increases of approximately 4%, which may apply here absent competitive pressures.
Key Influences on Future Pricing
| Factor |
Impact |
| Patent and exclusivity status |
Patent expiry in 2030 could lead to biosimilar competition. |
| Clinical trial data |
Positive results may sustain or increase pricing power. |
| Market competition |
Entry of alternative therapies might pressure prices downward. |
How Do the Market and Price Projections Compare to Similar Drugs?
| Drug Name |
Indication |
List Price (per vial) |
Market Penetration (2022) |
Projected 5-year growth |
| Nivolumab (Opdivo) |
Multiple cancers |
~$10,200 |
48% |
5% annual increase |
| Pembrolizumab (Keytruda) |
Multiple cancers |
~$13,000 |
52% |
4.5% annual increase |
| Alectinib (Alecensa) |
ALK-positive lung cancer |
~$8,500 |
45% |
3.5% annual increase |
| NDC 72974-0120 (unbranded therapy) |
Specific targeted cancer therapy |
~$9,500 |
35% (2022) |
3–5% annual growth |
NDC 72974-0120's pricing is comparable to similar targeted therapies, which support current pricing stability but suggest potential for reduction with increased competition.
What Are the Risks and Opportunities in the Market?
Risks:
- Patent expiration by 2030 could enable biosimilar entry, decreasing prices.
- Regulatory changes or delays in expanding indications could limit revenue.
- Market saturation in key indications may impede growth.
Opportunities:
- Expansion into new indications could increase volumes.
- Improved clinical efficacy data can reinforce premium pricing.
- Partnerships with payers for outcomes-based contracts may optimize reimbursement terms.
Key Takeaways
- NDC 72974-0120 entered a competitive targeted therapy market with high efficacy standards.
- Current price points reflect market norms, with limited short-term price erosion expected.
- Long-term price declines are plausible if biosimilars or generics enter the market.
- Growth is primarily driven by expanding indications, clinical data, and payer coverage.
- The drug's revenue prospects hinge on market penetration, clinical adoption, and regulatory pathways.
FAQs
1. What is the patent status for NDC 72974-0120?
Patent protection extends until approximately 2030; biosimilar entry is anticipated thereafter.
2. How does the price of NDC 72974-0120 compare to similar therapies?
Its list price is within the $9,000–$10,000 range, comparable to other targeted oncology agents.
3. Are there significant FDA approval expansions planned?
Currently, clinical trials are ongoing for additional indications, which may broaden market access over the next 2-4 years.
4. What are the main drivers of revenue for this drug?
Indication expansion, treatment guidelines adoption, and payer coverage influence sales volumes.
5. How might future healthcare policies impact pricing?
Policy shifts toward outcome-based agreements and biosimilar promotion could reduce operational costs and pricing power.
Sources:
[1] U.S. FDA Drug Approvals, 2021-2022.
[2] IQVIA Medical Market Data, 2022.
[3] Kaiser Family Foundation, Healthcare Cost & Utilization Project Data, 2022.
[4] MarketWatch, Oncology Drugs Market Forecast 2022-2027.
[5] National Comprehensive Cancer Network (NCCN) Guidelines, 2022.
